Focused Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-53
Closed -$3.57K – 384
2023
Q4
$3.57K Hold
53
– – ﹤0.01% 708
2023
Q3
$3.82K Hold
53
– – ﹤0.01% 687
2023
Q2
$3.92K Hold
53
– – ﹤0.01% 714
2023
Q1
$2.81K Hold
53
– – ﹤0.01% 758
2022
Q4
$3.57K Hold
53
– – ﹤0.01% 716
2022
Q3
$7K Hold
53
– – ﹤0.01% 550
2022
Q2
$5K Buy
+53
New +$6.46K ﹤0.01% 604

Other funds holding DNA

Focused Wealth Management's DNA Position: Q1 2024 in Review

Focused Wealth Management sold out of Ginkgo Bioworks (DNA) in Q1 2024, closing a stake of 53 shares — an estimated $3.57K sold.

Focused Wealth Management first reported a position in DNA in Q2 2022 and held it in 7 quarters. The position peaked at $7K in Q3 2022. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

  • Focused Wealth Management reported no remaining Ginkgo Bioworks position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 53 Ginkgo Bioworks shares in Q1 2024, an estimated $3.57K.
  • Focused Wealth Management first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 7 quarters.
  • Focused Wealth Management's Ginkgo Bioworks position peaked at $7K in Q3 2022.
  • 342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.